Real-life Study of the Characteristics of Patients Treated With Ilaris® (Canakinumab) for Gouty Arthritis in France

Gouty Arthritis Clinical Trial

Official title:
Real-life Study of the Characteristics of Patients Treated With Ilaris® (Canakinumab) for Gouty Arthritis in France

Status Completed

Clinical Trial Summary

This was a non-interventional, retrospective, cross-sectional, descriptive study, conducted on the National Health Data System (Système National des Données de Santé, SNDS). The study did not modify the doctor-patient relationship, nor the management or follow-up of patients. Patients with dispensation of canakinumab for gouty arthritis were selected over the period from 08 April 2018 to 07 April 2020; index date was defined as date of the first dispensation of canakinumab in community pharmacy during study period. Patients were described at index date. Medical history and comorbidities, and previous treatments for gouty arthritis were assessed during 3 years prior to index date. Co-treatments of interest for which standard treatments for gouty arthritis were contraindicated or required precautions for use were assessed during 6 months prior to index date.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05964946
Study type	Observational
Source	Novartis
Contact
Status	Completed
Phase
Start date	June 24, 2020
Completion date	July 29, 2022

View Details

See also
Status	Clinical Trial	Phase
Not yet recruiting	`NCT06068478` - A Study to Evaluate Efficacy and Safety of Qingzhu Granules in the Treatment of Acute Gouty Arthritis	Phase 3
Recruiting	`NCT01867840` - Role of ASICs in Human Inflammatory Pain	N/A
Completed	`NCT00927810` - Long Term Study of Canakinumab (ACZ885) in Patients With Gout	Phase 2
Completed	`NCT05332795` - The Impact of Metformin on the Outcome of Gouty Arthritis in a Cohort of Egyptian Gouty Patients.	N/A
Terminated	`NCT01362608` - Safety & Efficacy of Canakinumab (ACZ885) in Patients With Frequent Flares for Whom Nonsterodial Anti-Inflammatory Drug (NSAIDs) and/ or Colchicine Are Contraindicated, Not Tolerated or Ineffective	Phase 3
Completed	`NCT01626235` - AMPED Outcomes Registry of Post-ED Pain Management	N/A
Not yet recruiting	`NCT04462666` - Oral Huzhang Granules for Acute Gouty Arthritis	Phase 2
Recruiting	`NCT05658575` - Study of Dapansutrile Tablets in Subjects With an Acute Gout Flare	Phase 2/Phase 3